E.g., 11/19/2019
E.g., 11/19/2019
Title Category Credit Event date Price
Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018).
Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-Based Discussion - Washington, D.C. (...
    • 5.75 AMA PRA Category 1 Credit™
    • 5.75 Non-Physician Participation
12/03/2019 $0.00 Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC Webcast 013IC (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Highlights from AUA2019: Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer (2019) $0.00 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
Highlights in Renal Cell Carcinoma: Coordination of Care & the Patient's Journey (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights in Renal Cell Carcinoma: The Evolving Landscape of Adjuvant Therapy (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists. 
Highlights in Renal Cell Carcinoma: The Roles of the Urologist and Medical Oncologist (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights in the Medical Management of Urothelial Carcinoma: Advanced and Metastatic Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma (see below for a link to the activity)2) Management of Advanced and Metastatic Urothelial Carcinoma
Highlights in the Medical Management of Urothelial Carcinoma: Non-Muscle Invasive Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma 2) Management of Advanced and Metastatic Urothelial Carcinoma (see below for a link to the activity)
Immune Checkpoint Inhibitors in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Immuno-Oncology: A Focus on Prostate Cancer Webcast (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals. This is the fourth in a series of 4 webinars.
Immunotherapy: From Research to Practice Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics Webcast 077IC (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting.
Life Long Learning Knowledge Assessment Course: Upper Tract Tumors/Urinary Diversion Webcast (2018)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion. The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.
Life Long Learning Knowledge Assessment Course: Urothelial Bladder Cancer Webcast (2018)
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.

Pages